Free shipping on all orders over $ 500

CPI-0610

Cat. No. M2202
CPI-0610 Structure
Synonym:

Pelabresib

Size Price Availability Quantity
5mg USD 220  USD220 In stock
10mg USD 330  USD330 In stock
25mg USD 650  USD650 In stock
50mg USD 950  USD950 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

CPI-0610 is a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. The BET inhibitor CPI-0610 binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides.

Chemical Information
Molecular Weight 365.81
Formula C20H16ClN3O2
CAS Number 1380087-89-7
Solubility (25°C) 73 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Douglas Tremblay, et al. Next Generation Therapeutics for the Treatment of Myelofibrosis

[2] Sangeetha Venugopal, et al. Current Clinical Investigations in Myelofibrosis

[3] Jigar Raythatha, et al. The future of epigenetic therapy: CPI-0610 for the treatment of myeloidfibrosis

[4] K T Siu, et al. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma

[5] Brian K Albrecht, et al. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

Related Epigenetic Reader Domain Products
Phoenixin-20

Phoenixin-20 (PNX-20) is a bioactive peptide with hormone-like actions in vertebrates, and can stimulates hypothalamo-pituitary-gonadal hormones and regulate reproductive processes in mammals.

Menin-MLL inhibitor 31

Menin-MLL inhibitor 31 is a potent inhibitor of the menin MLL interaction with an IC50 value of 4.6 nM.

OPN-2853

OPN-2853 is a bromodomain protein-4 (BRD4) inhibitor that can be used in studies related to hematologic and lymphatic disorders.

HDAC/JAK/BRD4-IN-1

HDAC/JAK/BRD4-IN-1 is a potent HDAC/JAK/BRD4 triple inhibitor.

VYN-201

VYN-201 is a novel pan-BET inhibitor for studies related to idiopathic pulmonary fibrosis.

  Catalog
Abmole Inhibitor Catalog




Keywords: CPI-0610, Pelabresib supplier, Epigenetic Reader Domain, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.